Show summary Hide summary
New research suggests a commonly used cholesterol panel may miss people at risk for heart attack and stroke. A study published in JAMA in April and led by Northwestern Medicine researchers found that measuring apolipoprotein B (apoB) can reveal elevated risk that routine LDL or non‑HDL tests sometimes fail to detect.
Why this matters today
Heart disease and stroke remain the top causes of death in the United States, so improvements in how risk is identified could change who receives preventive treatment. If apoB testing becomes more widely used, some patients currently judged low risk by standard panels might be reclassified and offered earlier intervention.
Kyiv neighborhood under constant bombardment: residents refuse to flee
Cholesterol test being skipped could leave heart risks undetected: what to know
What is apoB?
ApoB is a protein on the surface of lipoprotein particles that carry cholesterol through the bloodstream. These particles are the ones that can embed cholesterol in artery walls and contribute to plaque buildup over time. Because apoB counts the number of atherogenic particles rather than just the cholesterol mass they carry, it can give a different picture of risk.
The American Heart Association notes that LDL cholesterol can appear normal while apoB levels are raised — a mismatch that a basic lipid panel may not reveal. That discordance is exactly what the JAMA study examined.
How the main tests compare
- ApoB: Measures the number of cholesterol-bearing particles linked to artery buildup; may detect risk missed by other tests.
- LDL cholesterol: Often called “bad” cholesterol; reports the cholesterol content carried in LDL particles but not particle number.
- Non‑HDL cholesterol: Total cholesterol minus HDL; captures all atherogenic cholesterol but still reflects mass rather than particle count.
- Lipoprotein(a) — Lp(a): A genetically determined particle associated with long‑term cardiovascular risk; current guidance recommends measuring it at least once in adulthood.
All of these measurements require a blood sample; differences lie in what each test quantifies and how that information informs risk assessment and treatment decisions.
Who could be reclassified?
People whose LDL or non‑HDL cholesterol appears within acceptable ranges but who have elevated apoB could be at higher risk than their standard results imply. That group may include individuals with metabolic syndrome, certain genetic lipid disorders, or those whose particles are smaller and denser — characteristics not always reflected by LDL numbers alone.
Earlier this year, major cardiovascular societies — including the American Heart Association and the American College of Cardiology — updated screening guidance to highlight tests such as Lp(a). The JAMA findings add momentum to calls for broader use of particle‑focused measurements in select patients.
What happens next will depend on clinical adoption: whether insurers and health systems expand access to apoB testing, and whether clinicians start incorporating it routinely into risk discussions. For patients, the takeaway is simple: if you or your clinician are uncertain about cardiovascular risk despite a “normal” lipid panel, ask whether additional testing such as apoB or Lp(a) might clarify your situation.
